Overall market sentiment has been high on Regulus Therapeutics Inc (RGLS) stock lately. RGLS receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With RGLS Stock Today?
Regulus Therapeutics Inc (RGLS) stock is down -2.7% while the S&P 500 has gained 0.88% as of 2:36 PM on Friday, Jun 4. RGLS has fallen -$0.03 from the previous closing price of $1.11 on volume of 1,214,141 shares. Over the past year the S&P 500 is higher by 35.44% while RGLS has gained 35.00%. RGLS lost -$0.39 per share in the over the last 12 months.
To screen for more stocks like Regulus Therapeutics Inc click here.
More About Regulus Therapeutics Inc
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
Click Here to get the full Stock Score Report on Regulus Therapeutics Inc (RGLS) Stock.
